Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$1.30
▼ $0.02 (-1.5%)
Market data updated: 09/19 02:28 PM
Fundamentals updated: 09/19/2026
News analyzed: 09/19/2026
Market Cap
$835.22M
Day Range
$1.29 - $1.33
52-Week Range
$1.04 - $2.01
Beta
—
Next Earnings
03.11.2026
Support
$1.22
Resistance
$1.65
GERN is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-1.5% (1Y)
Strengths: 5/25 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: 51.9%
Growth
Biggest negative driver
Operating margin stability
Operating margin is eroding over time
Quality
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
47
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
66
Quality
42
Value
50
Momentum
23
Risk
40
Sentiment
80
Fundamental
46
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Geron Corporation has centered on its financial performance and investor outreach. The company reported strong Q2 2026 revenue growth of 11% for its myelofibrosis drug, Rytelo, reaching $57.5 million in U.S. sales, alongside updated guidance and narrowing losses. Analysts debated its valuation, with some calling it undervalued while others questioned profitability. Geron’s leadership is also scheduled to participate in investor conferences, including the Cantor Global Healthcare Conference, to discuss its strategic direction amid rising competition in the myelofibrosis market.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Geron Corporation. News trend score: 80. Reason: 8 of the last 20 articles are positive, versus 3 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
26
🎯 Conviction (vs. Emotion)
48
Psychology
60
Fundamentals
46
Technical
23
Valuation
50
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+3%
Market Narrative
45
Fundamental Reality
48
Narrative Gap
-3
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
GERN’s psychology is fragmented, with **FOMO** (22) as the highest but unconfirmed state, driven by elevated volume and neutral RSI. The narrative gap (2 points) suggests minor misalignment, but no dominant bias dominates. Herding (11) hints at peer-driven moves, while Euphoria (12) persists due to lingering above-average positioning. The absence of extreme states (e.g., panic, overconfidence) implies a cautious, reactive market. The key question: *Is the volume spike a buying opportunity or a warning sign?*
Updated: 09/09/2026, 05:03 AM
What could change this?
👥 What the crowd believes
"reported Q2'26 net product revenues of $57.5M from U.S. sales of Rytelo, up 11% from Q1'26"
"Geron (GERN) Is Up 14.7% After Issuing First RYTELO Revenue Guide"
"members of the management team are scheduled to participate in upcoming investor conferences"
📈 12D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Samuel Armstrong Nelson — 94/100
🔴 Weakest match
Jesse Livermore — 12/100
🗣️ Why do they disagree?
Based on Nelson’s documented principles, the model estimates that the stock’s cycle position looks favorable, which together with Bagehot’s strong liquidity view (score 92) and Mackay’s lack of crowd mania (score 82) leads these frameworks to see upside potential. Based on Lynch’s growth‑oriented criteria and Marks‑cycle’s market‑cycle timing, the model estimates that the price may still lag the company’s growth but the stock is not yet overextended (scores 75 and 68). Based on Graham’s value safety‑margin rules, Schwager’s edge analysis, and Loeb’s risk assessment, the model estimates mixed or moderate risk, indicating the stock does not clearly satisfy traditional value or safety‑margin tests (scores ranging from 52 to 44). Based on Fisher’s fundamental depth, Veblen’s social‑economic lens, and Livermore’s trend‑following rule, the model estimates significant concerns—insufficient data, speculative growth, and a negative trend—resulting in the lowest scores and largely unfavorable conclusions (scores 25, 18, and 9).
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 94
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 92
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 82
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 75
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 61
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 58
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 58
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 52
Mixed — doesn't clearly pass Graham's tests
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 44
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 44
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 42
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 35
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 30
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 25
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 20%
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 18
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 12
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (1 bullish · 9 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
—
Net Margin
—
EBITDA Margin
—
ROE
-37.0%
ROA
-14.6%
ROIC
—
EPS
-$0.13
Cash
$77.56M
Total Debt
$119.55M
Current Ratio
4.66
Debt/Equity
0.53
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
$0.34
Tangible Book Value per Share (Tangible NAV)
$0.34
Sentiment based on basic keywords (not AI) — 8 positive, 9 neutral, 3 negative out of the last 20 articles.
Yahoo · 18.9.2026
Yahoo · 16.9.2026
Yahoo · 13.9.2026
MarketBeat · 13.9.2026
Yahoo · 2.9.2026
GlobeNewswire · 2.9.2026
GlobeNewswire · 18.8.2026
SeekingAlpha · 18.8.2026
Simply Wall St. · 10.8.2026
Simply Wall St. · 9.8.2026
Simply Wall St. · 9.8.2026
Motley Fool · 6.8.2026
GuruFocus.com · 5.8.2026
Moby · 5.8.2026
MarketBeat · 5.8.2026
Zacks · 5.8.2026
ChartMill · 5.8.2026
Associated Press · 5.8.2026
SeekingAlpha · 5.8.2026
GlobeNewswire · 5.8.2026
Geron Corporation (GERN) currently has a StockIQ AI score of 47/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
GERN currently scores 47/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
GERN's technical score is 23/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: 51.9%; Net income growth: 52.2%; Current ratio: 4.66.
Based on the real signals StockIQ computed: Operating margin is eroding over time; ATR: 5.9% of price; Calmar: -0.20 (3y annualized return -16.0% / max drawdown 79.0%).
StockIQ has no recorded dividend payment history for GERN.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 2 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Spiegel Robert J. | Grant/Award from Employer | 30.6.2026 | 6,103 | +6,103 | $1.28 |
| Spiegel Robert J. | Grant/Award from Employer | 30.6.2026 | 205,810 | +6,103 | $1.28 |
| Bir Dawn Carter | Grant/Award from Employer | 20.5.2026 | 220,000 | +220,000 | — |
| Spiegel Robert J. | Grant/Award from Employer | 20.5.2026 | 220,000 | +220,000 | — |
| Molineaux Susan | Grant/Award from Employer | 20.5.2026 | 220,000 | +220,000 | — |
| McDonald John F | Grant/Award from Employer | 20.5.2026 | 220,000 | +220,000 | — |
| O'Farrell Elizabeth G. | Grant/Award from Employer | 20.5.2026 | 220,000 | +220,000 | — |
| Spiegel Robert J. | Grant/Award from Employer | 20.5.2026 | 220,000 | +220,000 | — |
| Molineaux Susan | Grant/Award from Employer | 20.5.2026 | 220,000 | +220,000 | — |
| Bir Dawn Carter | Grant/Award from Employer | 20.5.2026 | 220,000 | +220,000 | — |
| O'Farrell Elizabeth G. | Grant/Award from Employer | 20.5.2026 | 220,000 | +220,000 | — |
| McDonald John F | Grant/Award from Employer | 20.5.2026 | 220,000 | +220,000 | — |
| Williams Timothy | Grant/Award from Employer | 13.4.2026 | 2,500,000 | +2,500,000 | — |
| Williams Timothy | Grant/Award from Employer | 13.4.2026 | 2,500,000 | +2,500,000 | — |
| Spiegel Robert J. | Grant/Award from Employer | 31.3.2026 | 5,243 | +5,243 | $1.49 |
| Spiegel Robert J. | Grant/Award from Employer | 31.3.2026 | 199,707 | +5,243 | $1.49 |
| Andrews Patricia S | Grant/Award from Employer | 25.3.2026 | 270,000 | +270,000 | — |
| Chinoporos Constantine | Grant/Award from Employer | 25.3.2026 | 270,000 | +270,000 | — |
| Andrews Patricia S | Grant/Award from Employer | 25.3.2026 | 270,000 | +270,000 | — |
| Chinoporos Constantine | Grant/Award from Employer | 25.3.2026 | 270,000 | +270,000 | — |
| ROBERTSON MICHELLE | Exercise of Derivative Securities | 18.2.2026 | 27,500 | +27,500 | — |
| ROBERTSON MICHELLE | Exercise of Derivative Securities | 18.2.2026 | 27,500 | -27,500 | — |
| ROBERTSON MICHELLE | Open Market Sale | 18.2.2026 | 9,855 | -9,855 | $1.94 |
| ROBERTSON MICHELLE | Exercise of Derivative Securities | 18.2.2026 | 27,500 | +27,500 | — |
| ROBERTSON MICHELLE | Open Market Sale | 18.2.2026 | 17,645 | -9,855 | $1.94 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
85,093,515 shares short as of 2026-08-31 · vs. 76,807,284 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
48.6% of trading volume this week was short selling, vs. 55.6% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology